search
Back to results

Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder

Primary Purpose

Anxiety in Those Patients With Anorexia Nervosa, Eating Disorder Not Otherwise Specified, BMI (<=18)

Status
Withdrawn
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Hydroxyzine
hydroxyzine HCL
Placebo
Sponsored by
HealthPartners Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anxiety in Those Patients With Anorexia Nervosa focused on measuring Treating meal related anxiety

Eligibility Criteria

8 Years - 25 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Admitted to the Intensive Structured Living Unit (ISL) at Melrose Institute for treatment of an eating disorder that meets DSM-IV criteria for Anorexia Nervosa (excluding the amenorrhea criterion), or Eating Disorder Not Otherwise Specified, specifically with BMI (≤ 18)
  • Age 8-25 years old at admission to ISL.
  • Weight ≥ 15 kg at admission to ISL.
  • Stable psychotropic and/or sedative medications for at least (≥) 6 weeks

Exclusion Criteria:

  • Age < 8 years
  • Age ≥ 25 years
  • Weight < 15 kg at admission to ISL
  • Prolonged QT interval on ECG at admission to ISL
  • Current substance or alcohol abuse or dependence
  • Malabsorption syndrome or inability to take oral medications
  • History of hydroxyzine intolerance or hypersensitivity
  • History of Type 1 Diabetes Mellitus
  • History of angle closure glaucoma
  • Currently on another clinical trial
  • Pregnancy

Sites / Locations

  • Melrose Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Hydroxyzine

Sugar Pill

Arm Description

Hydroxyzine given TID

Placebo given 3 times per day

Outcomes

Primary Outcome Measures

Self-reported anxiety

Secondary Outcome Measures

Full Information

First Posted
June 10, 2011
Last Updated
November 14, 2016
Sponsor
HealthPartners Institute
Collaborators
Park Nicollet Eating Disorder Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT01372670
Brief Title
Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder
Official Title
Hydroxyzine Effects on Meal-Related Anxiety in Underweight Adolescents and Young Adults Diagnosed With an Eating Disorder - A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
February 2016
Overall Recruitment Status
Withdrawn
Why Stopped
Due to unforseen recruiting difficulties, the study was closed.
Study Start Date
January 2012 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
April 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
HealthPartners Institute
Collaborators
Park Nicollet Eating Disorder Institute

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine the effectiveness of hydroxyzine in the treatment of meal-related anxiety in adolescents and young adults 8 to 25 years of age diagnosed with an eating disorder who are underweight. The investigators want to find out if hydroxyzine given before meals will improve meal-related anxiety compared to no hydroxyzine.
Detailed Description
This study is a practiced-based pilot study in follow-up to clinical observations made by our treatment team that hydroxyzine attenuates meal-related anxiety and improves treatment adherence in patients with a diagnosis of Anorexia Nervosa (AN) (excluding the amenorrhea criterion) or Eating Disorder Not Otherwise Specified (EDNOS) specifically with low BMI (≤ 18). To our knowledge, hydroxyzine has never been formally investigated in treating meal-related anxiety and improving outcomes in patients with AN or EDNOS specifically with low BMI (≤ 18).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anxiety in Those Patients With Anorexia Nervosa, Eating Disorder Not Otherwise Specified, BMI (<=18)
Keywords
Treating meal related anxiety

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Hydroxyzine
Arm Type
Experimental
Arm Description
Hydroxyzine given TID
Arm Title
Sugar Pill
Arm Type
Placebo Comparator
Arm Description
Placebo given 3 times per day
Intervention Type
Drug
Intervention Name(s)
Hydroxyzine
Intervention Description
Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges: 15-29 Kg 10 mg TID 30-44 Kg 20 mg TID ≥ 45 Kg 30 mg TID
Intervention Type
Drug
Intervention Name(s)
hydroxyzine HCL
Intervention Description
hydroxyzine HCL dosed on weight given 3x per day
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
Placebo given 3 times per day
Primary Outcome Measure Information:
Title
Self-reported anxiety
Time Frame
3 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
25 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Admitted to the Intensive Structured Living Unit (ISL) at Melrose Institute for treatment of an eating disorder that meets DSM-IV criteria for Anorexia Nervosa (excluding the amenorrhea criterion), or Eating Disorder Not Otherwise Specified, specifically with BMI (≤ 18) Age 8-25 years old at admission to ISL. Weight ≥ 15 kg at admission to ISL. Stable psychotropic and/or sedative medications for at least (≥) 6 weeks Exclusion Criteria: Age < 8 years Age ≥ 25 years Weight < 15 kg at admission to ISL Prolonged QT interval on ECG at admission to ISL Current substance or alcohol abuse or dependence Malabsorption syndrome or inability to take oral medications History of hydroxyzine intolerance or hypersensitivity History of Type 1 Diabetes Mellitus History of angle closure glaucoma Currently on another clinical trial Pregnancy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marcus Westerman, MD, PhD
Organizational Affiliation
Park Nicollet Melrose Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Melrose Institute
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55416
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder

We'll reach out to this number within 24 hrs